TAXUS IV Data Suggest Advantage For Paclitaxel-Eluting Stent In Diabetics
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific is emphasizing the performance of its Taxus paclitaxel-eluting stent in diabetic patients as a possible edge over rival Johnson & Johnson's Cypher sirolimus-eluting stent